Loading...

Akebia Therapeutics

Nasdaq:AKBA
Snowflake Description

High growth potential and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AKBA
Nasdaq
$618M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The last earnings update was 17 days ago. More info.


Add to Portfolio Compare Print
  • Akebia Therapeutics has significant price volatility in the past 3 months.
AKBA Share Price and Events
7 Day Returns
-4.7%
NasdaqGM:AKBA
0.3%
US Biotechs
-1.4%
US Market
1 Year Returns
-49.1%
NasdaqGM:AKBA
-4.9%
US Biotechs
1.6%
US Market
AKBA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Akebia Therapeutics (AKBA) -4.7% -17.7% -29.8% -49.1% -40.5% -78.4%
US Biotechs 0.3% -1.4% -4.9% -4.9% 3.6% 11%
US Market -1.4% -3.9% 0.2% 1.6% 33.2% 38.2%
1 Year Return vs Industry and Market
  • AKBA underperformed the Biotechs industry which returned -4.9% over the past year.
  • AKBA underperformed the Market in United States of America which returned 1.6% over the past year.
Price Volatility
AKBA
Industry
5yr Volatility vs Market

AKBA Value

 Is Akebia Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Akebia Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Akebia Therapeutics.

NasdaqGM:AKBA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 9 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.5%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:AKBA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.38
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.383 (1 + (1- 21%) (5.83%))
1.299
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.299 * 5.96%)
10.47%

Discounted Cash Flow Calculation for NasdaqGM:AKBA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Akebia Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGM:AKBA DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 10.47%)
2019 -226.00 Analyst x1 -204.58
2020 -142.01 Analyst x2 -116.36
2021 -15.66 Analyst x2 -11.61
2022 109.69 Analyst x1 73.65
2023 211.68 Analyst x1 128.65
2024 307.52 Est @ 45.28% 169.19
2025 407.50 Est @ 32.51% 202.94
2026 503.58 Est @ 23.58% 227.02
2027 590.82 Est @ 17.32% 241.10
2028 667.30 Est @ 12.95% 246.50
Present value of next 10 years cash flows $956.50
NasdaqGM:AKBA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $667.30 × (1 + 2.73%) ÷ (10.47% – 2.73%)
$8,855.03
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $8,855.03 ÷ (1 + 10.47%)10
$3,271.03
NasdaqGM:AKBA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $956.50 + $3,271.03
$4,227.52
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $4,227.52 / 117.86
$35.87
NasdaqGM:AKBA Discount to Share Price
Calculation Result
Value per share (USD) From above. $35.87
Current discount Discount to share price of $5.24
= -1 x ($5.24 - $35.87) / $35.87
85.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Akebia Therapeutics is available for.
Intrinsic value
>50%
Share price is $5.24 vs Future cash flow value of $35.87
Current Discount Checks
For Akebia Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Akebia Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Akebia Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Akebia Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Akebia Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:AKBA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-2.56
NasdaqGM:AKBA Share Price ** NasdaqGM (2019-05-24) in USD $5.24
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 18.23x
United States of America Market PE Ratio Median Figure of 3,084 Publicly-Listed Companies 17.44x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Akebia Therapeutics.

NasdaqGM:AKBA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:AKBA Share Price ÷ EPS (both in USD)

= 5.24 ÷ -2.56

-2.04x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Akebia Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Akebia Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Akebia Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:AKBA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.04x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
71.4%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.22x
United States of America Market PEG Ratio Median Figure of 2,121 Publicly-Listed Companies 1.51x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Akebia Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Akebia Therapeutics's assets?
Raw Data
NasdaqGM:AKBA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $4.84
NasdaqGM:AKBA Share Price * NasdaqGM (2019-05-24) in USD $5.24
United States of America Biotechs Industry PB Ratio Median Figure of 416 Publicly-Listed Biotechs Companies 3.17x
United States of America Market PB Ratio Median Figure of 5,207 Publicly-Listed Companies 1.8x
NasdaqGM:AKBA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:AKBA Share Price ÷ Book Value per Share (both in USD)

= 5.24 ÷ 4.84

1.08x

* Primary Listing of Akebia Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Akebia Therapeutics is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Akebia Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Akebia Therapeutics has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AKBA Future Performance

 How is Akebia Therapeutics expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
71.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Akebia Therapeutics expected to grow at an attractive rate?
  • Akebia Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Akebia Therapeutics's earnings growth is expected to exceed the United States of America market average.
  • Akebia Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:AKBA Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:AKBA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 71.4%
NasdaqGM:AKBA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 20.2%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:AKBA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:AKBA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 732 424 4
2022-12-31 567 295 4
2021-12-31 418 -152 66 6
2020-12-31 366 -41 -100 9
2019-12-31 351 -225 -155 8
NasdaqGM:AKBA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 234 -215 -193
2018-12-31 208 -97 -144
2018-09-30 235 -40 -71
2018-06-30 223 -82 -68
2018-03-31 206 -67 -53
2017-12-31 181 -56 -74
2017-09-30 92 56 -127
2017-06-30 51 82 -140
2017-03-31 22 31 -154
2016-12-31 2 58 -136
2016-09-30 -61 -118
2016-06-30 -41 -101

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Akebia Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Akebia Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:AKBA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from Akebia Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:AKBA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.88 2.95 2.81 2.00
2022-12-31 2.06 2.12 2.00 2.00
2021-12-31 0.50 0.50 0.50 1.00
2020-12-31 -0.62 -0.22 -0.90 6.00
2019-12-31 -1.35 -0.72 -1.80 7.00
NasdaqGM:AKBA Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -2.56
2018-12-31 -2.47
2018-09-30 -1.36
2018-06-30 -1.37
2018-03-31 -1.14
2017-12-31 -1.69
2017-09-30 -3.08
2017-06-30 -3.60
2017-03-31 -4.05
2016-12-31 -3.60
2016-09-30 -3.29
2016-06-30 -3.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Akebia Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Akebia Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Akebia Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AKBA Past Performance

  How has Akebia Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Akebia Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Akebia Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Akebia Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Akebia Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Akebia Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Akebia Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:AKBA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 234.48 -192.59 89.23
2018-12-31 207.74 -143.59 63.96
2018-09-30 235.21 -71.25 39.51
2018-06-30 223.32 -68.34 35.88
2018-03-31 206.29 -52.55 30.24
2017-12-31 181.23 -73.67 27.01
2017-09-30 92.20 -127.06 25.59
2017-06-30 50.92 -140.23 23.78
2017-03-31 22.40 -154.49 22.19
2016-12-31 1.54 -135.75 22.21
2016-09-30 -117.74 21.87 -28.77
2016-06-30 -100.91 21.00 -13.17
2016-03-31 -75.82 20.08 -6.56
2015-12-31 -60.72 18.50
2015-09-30 -51.23 18.07 33.61
2015-06-30 -41.10 17.23 24.65
2015-03-31 -38.03 15.18 23.57
2014-12-31 -123.93 14.68
2014-09-30 -122.54 12.01 21.52
2014-06-30 -119.70 9.57 18.11
2014-03-31 -164.18 7.90 15.04
2013-12-31 -69.05 7.03 8.90
2013-09-30 -63.34 3.44 8.16
2012-12-31 -11.52 2.89 5.63

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Akebia Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Akebia Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Akebia Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Akebia Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Akebia Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AKBA Health

 How is Akebia Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Akebia Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Akebia Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Akebia Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Akebia Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 9.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Akebia Therapeutics Company Filings, last reported 1 month ago.

NasdaqGM:AKBA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 566.38 35.98 168.04
2018-12-31 635.93 15.00 321.64
2018-09-30 142.54 0.00 390.14
2018-06-30 165.92 0.00 402.12
2018-03-31 197.10 0.00 393.03
2017-12-31 122.57 0.00 317.79
2017-09-30 99.88 0.01 329.71
2017-06-30 57.00 0.01 321.22
2017-03-31 30.62 0.01 251.81
2016-12-31 68.12 0.00 260.34
2016-09-30 100.71 0.01 161.32
2016-06-30 133.29 0.01 188.65
2016-03-31 167.76 0.01 217.03
2015-12-31 131.00 0.00 138.45
2015-09-30 145.41 0.00 157.47
2015-06-30 149.75 0.00 152.79
2015-03-31 94.61 0.00 100.33
2014-12-31 104.08 0.00 108.92
2014-09-30 113.61 0.00 118.34
2014-06-30 121.55 0.01 124.25
2014-03-31 127.87 0.01 132.15
2013-12-31 30.76 0.00 32.56
2013-09-30 35.57 0.00 37.72
2012-12-31 1.47 0.00 1.64
  • Akebia Therapeutics's level of debt (6.4%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 6.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Akebia Therapeutics has less than a year of cash runway based on current free cash flow.
  • Akebia Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 64.8% each year.
X
Financial health checks
We assess Akebia Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Akebia Therapeutics has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AKBA Dividends

 What is Akebia Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Akebia Therapeutics dividends. Estimated to be 0% next year.
If you bought $2,000 of Akebia Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Akebia Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Akebia Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:AKBA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2007 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:AKBA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Akebia Therapeutics has not reported any payouts.
  • Unable to verify if Akebia Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Akebia Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Akebia Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Akebia Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Akebia Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Akebia Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Akebia Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AKBA Management

 What is the CEO of Akebia Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Butler
COMPENSATION $3,471,072
AGE 54
TENURE AS CEO 5.7 years
CEO Bio

Mr. John P. Butler, MBA, has been the Chief Executive Officer and President of Akebia Therapeutics, Inc. since September 2013. Mr. Butler served as Chief Executive Officer of Inspiration Biopharmaceuticals, Inc. from October 11, 2011 to April 2013. He served as the President of Personalized Genetic Health at Genzyme Corporation since May 2010. He served as Senior Vice President and President of Cardiometabolic & Renal at Genzyme Corporation. He served as President of Renal business of Genzyme Corporation. He served as Senior Vice President and General Manager of the Renal business of Genzyme Corporation since July 16, 2003. Mr. Butler has more than 25 years of experience commercializing innovative therapies, leading businesses that served rare disease patient populations. He joined Genzyme in 1997 as Product Manager for Renagel and served as its Vice President of strategic planning and Vice President of Renagel Europe. He served as President of the Rare Genetic Diseases Business at Genzyme Corporation. From 2002 to 2010, Mr. Butler led Genzyme's renal division. Prior to his work at Genzyme from 1997 to 2011, he worked in sales and marketing at Amgen Inc., and Hoffmann-La Roche. He served as a Director of Relypsa, Inc. from September 26, 2013 to 2016. He has been a Director of Akebia Therapeutics, Inc. since July 2013. He has been a Chairperson of the Board of Keryx Biopharmaceuticals, Inc. since December 12, 2018. He has been a Director of Zynerba Pharmaceuticals, Inc. since April 2018. He was Chairman of Keryx Biopharmaceuticals from 2015 to 2017. He served as an Independent Director of Keryx Biopharmaceuticals Inc. from December 10, 2015 to September 13, 2017. He served as a Director of Inspiration Biopharmaceuticals, Inc. He served as Chairman of the Board of Trustees for the American Kidney Fund from 2013 to 2015. Mr. Butler has an M.B.A. from Baruch College, City University of New York and a B.A. in Chemistry from Manhattan College.

CEO Compensation
  • John's compensation has increased whilst company is loss making.
  • John's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Akebia Therapeutics management team in years:

3.6
Average Tenure
52
Average Age
  • The tenure for the Akebia Therapeutics management team is about average.
Management Team

John Butler

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
54
TENURE
5.7 yrs

Jason Amello

TITLE
Senior VP
COMPENSATION
$1M
AGE
50
TENURE
5.7 yrs

Rita Jain

TITLE
Senior VP & Chief Medical Officer
COMPENSATION
$1M
AGE
56
TENURE
2 yrs

Kristen Sheppard

TITLE
Vice President of Investor Relations

Nikki Hadas

TITLE
SVP, Chief Legal Officer & Secretary
AGE
45
TENURE
6.3 yrs

Doug Jermasek

TITLE
Vice President of Marketing & Strategy

Tamara Dillon

TITLE
Senior Vice President of Human Resources
TENURE
2.5 yrs

Michel Dahan

TITLE
Senior VP & Chief Business Officer
COMPENSATION
$1M
AGE
39
TENURE
3.6 yrs

Karen Tubridy

TITLE
Senior VP & Chief Development Officer
AGE
56
TENURE
2.5 yrs

Dell Faulkingham

TITLE
Senior VP & Chief Commercial Officer
Board of Directors Tenure

Average tenure and age of the Akebia Therapeutics board of directors in years:

0.6
Average Tenure
62.5
Average Age
  • The average tenure for the Akebia Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Adrian Adams

TITLE
Chairperson
COMPENSATION
$133K
AGE
67
TENURE
0.4 yrs

John Butler

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
54
TENURE
5.8 yrs

Cynthia Smith

TITLE
Director
COMPENSATION
$155K
AGE
49
TENURE
0.8 yrs

Michael Rogers

TITLE
Director
COMPENSATION
$133K
AGE
58
TENURE
0.4 yrs

Randall Johnson

TITLE
Advisor & Member of Scientific Advisory Board
AGE
71

John Adamson

TITLE

Peter Hutt

TITLE
AGE
83

Frank Bunn

TITLE

Suzette Dutch

TITLE
Observer

Volker Haase

TITLE
Advisor & Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
21. Dec 18 Sell Nantahala Capital Management, LLC Company 22. Oct 18 17. Dec 18 -99,931 $8.61 $-844,804
21. Dec 18 Buy Nantahala Capital Management, LLC Company 20. Nov 18 20. Dec 18 410,577 $8.50 $2,965,981
26. Sep 18 Buy Nantahala Capital Management, LLC Company 07. Aug 18 10. Sep 18 201,100 $9.99 $1,761,812
X
Management checks
We assess Akebia Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Akebia Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AKBA News

Simply Wall St News

Do Institutions Own Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares?

Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … We also tend to see lower insider ownership in companies that were previously publicly owned. … It has a market capitalization of US$955m, which means it would generally expect to see some institutions on the share registry.

Simply Wall St -

Some Akebia Therapeutics Shareholders Have Copped A Big 50% Share Price Drop

(NASDAQ:AKBA) shareholders should be happy to see the share price up 29% in the last month. … Like an arid lake in a warming world, shareholder value has evaporated, with the share price down 50% in that time. … Akebia Therapeutics isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS).

Simply Wall St -

What does Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Balance Sheet Tell Us About Its Future?

(NASDAQ:AKBA), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … While AKBA has no debt on its balance sheet, it doesn’t necessarily mean it exhibits financial strength. … Does AKBA's growth rate justify its decision for financial flexibility over lower cost of capital

Simply Wall St -

How Does Akebia Therapeutics, Inc. (NASDAQ:AKBA) Affect Your Portfolio Volatility?

(NASDAQ:AKBA), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility).

Simply Wall St -

How Much is Akebia Therapeutics Inc's (NASDAQ:AKBA) CEO Getting Paid?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does John Butler's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that Akebia Therapeutics Inc has a market cap of US$396m, and is paying total annual CEO compensation of US$3.4m

Simply Wall St -

How Financially Strong Is Akebia Therapeutics Inc (NASDAQ:AKBA)?

The direct benefit for Akebia Therapeutics Inc (NASDAQ:AKBA), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … However, the trade-off is AKBA will have to adhere to stricter debt covenants and have less financial flexibility. … Is financial flexibility worth the lower cost of capital.

Simply Wall St -

Is Akebia Therapeutics Inc's (NASDAQ:AKBA) CEO Incentives Align With Yours?

John Butler is the CEO of Akebia Therapeutics Inc (NASDAQ:AKBA), which has recently grown to a market capitalization of US$565.72m. … Recognizing whether CEO incentives are aligned with shareholders is a crucial part of investing. … This is because, if incentives are aligned, more value is created for shareholders which directly impacts your returns as an investor.

Simply Wall St -

What You Must Know About Akebia Therapeutics Inc's (NASDAQ:AKBA) Financial Strength

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is financial flexibility worth the lower cost of capital … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.

Simply Wall St -

Will Akebia Therapeutics Inc's (NASDAQ:AKBA) Earnings Grow Over The Next Few Years?

Akebia Therapeutics Inc's (NASDAQ:AKBA) most recent earnings update in December 2017 indicated that losses became smaller relative to the prrior year's level as a result of recent tailwinds Investors may find it useful to understand how market analysts view Akebia Therapeutics's earnings growth outlook over the next few years and whether the future looks brighter. … NasdaqGM:AKBA Future Profit May 7th 18 While it’s informative understanding the growth rate year by year relative to today’s value, it may be more valuable gauging the rate at which the company is growing on average every year. … This means that, we can presume Akebia Therapeutics will grow its earnings by 33.20% every year for the next couple of years.

Simply Wall St -

When Will Akebia Therapeutics Inc (NASDAQ:AKBA) Become Profitable?

Akebia Therapeutics Inc's (NASDAQ:AKBA): Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. … View our latest analysis for Akebia Therapeutics Expectation from analysts is AKBA is on the verge of breakeven. … This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

Simply Wall St -

AKBA Company Info

Description

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Details
Name: Akebia Therapeutics, Inc.
AKBA
Exchange: NasdaqGM
Founded: 2007
$617,599,982
117,862,592
Website: http://www.akebia.com
Address: Akebia Therapeutics, Inc.
245 First Street,
Suite 1400,
Cambridge,
Massachusetts, 02142,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM AKBA Common Stock Nasdaq Global Market US USD 20. Mar 2014
DB AX9 Common Stock Deutsche Boerse AG DE EUR 20. Mar 2014
Number of employees
Current staff
Staff numbers
325
Akebia Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/26 00:40
End of day share price update: 2019/05/24 00:00
Last estimates confirmation: 2019/05/15
Last earnings filing: 2019/05/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.